Business
Hemostemix Announces Its AI Strategy
Calgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF)...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Its AI StrategyCalgary, Alberta--(Newsfile Corp. - August 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\"), the leading autologous (patient's own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August 21, 2025. Croom Lawrence, Chief Commercialization Officer, Hemostemix, who completed executive education in Artificial Intelligence and Healthcare at the Massachusetts Institute of Technology (MIT), will present the Company's phased approach to embedding AI across its patient engagement, clinical research and corporate operations.\"This webinar will showcase how we are applying artificial intelligence to transform every aspect of Hemostemix into the world's first AI-driven autologous stem cell therapy company treating pain associated with no-option patients who can be treated under Florida's SB1768,\" stated Thomas Smeenk, CEO. \"We know the future of regenerative medicine is physician-based AI-enabled workflows\"  said Croom Lawrence, CCO. \"AI-based workflows generate a better patient experience, generates better recruitment, faster trials, best in class analytics, stronger patient outcomes, and more efficient patient care,\" Lawrence said.Patient Care InnovationsHIPAA-Compliant Precision Medicine Diagnostics - The platform unifies patient records, medications, co-morbidities, genetics, gut microbiome, and lifestyle data (exercise, diet, consumption patterns) into a single AI-powered analysis. This helps physicians see the patient's full health journey while showing patients how lifestyle choices impact outcomes.Acurist.AI for Early Cognitive Decline - Leveraging mild cognitive impairment (MCI) screening, Hemostemix sets baseline assessments to monitor subtle memory changes before and after VesCell™ (ACP-01) treatment. Get yours today ([email protected])AI-Powered Patient Engagement - Around-the-clock personalized chatbot support improves access and satisfaction while securely guiding patients through treatment, recovery, and lifestyle adjustments.Patient Decision Support Tools - AI-driven insights assist physicians and healthcare coaches in tailoring plans that help pa...